ID

33478

Descrição

Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation (n3); ODM derived from: https://clinicaltrials.gov/show/NCT01810003

Link

https://clinicaltrials.gov/show/NCT01810003

Palavras-chave

  1. 10/12/2018 10/12/2018 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

10 de dezembro de 2018

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Cardiovascular Disease, Inflammation NCT01810003

Eligibility Cardiovascular Disease, Inflammation NCT01810003

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
men and women aged between 18 and 70 years with metabolic syndrome as defined by the international diabetes federation (idf) criteria
Descrição

Age | Metabolic Syndrome

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0524620
stable body weight for at least 3 months prior to randomization.
Descrição

Stable body weight

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0517386
pre-menopausal women with regular menstrual cycle (25-35 days)
Descrição

Premenopausal state | Menstrual cycles regular

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0232969
UMLS CUI [2]
C2229012
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
plasma crp > 10 g/ml at screening
Descrição

Plasma C-reactive protein measurement

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0428493
extreme dyslipidemias such as familial hypercholesterolemia
Descrição

Dyslipidemias Extreme | Hypercholesterolemia, Familial

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0242339
UMLS CUI [1,2]
C0205403
UMLS CUI [2]
C0020445
previous history of cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease) and type 1 or 2 diabetes or patients having received or being treated with insulin or a thiazolidinedione within the past 6 months
Descrição

Cardiovascular Disease | Coronary heart disease | Cerebrovascular Disorder | Peripheral Arterial Disease | Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Non-Insulin-Dependent | Insulin | Thiazolidinediones

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C0010068
UMLS CUI [3]
C0007820
UMLS CUI [4]
C1704436
UMLS CUI [5]
C0011854
UMLS CUI [6]
C0011860
UMLS CUI [7]
C0021641
UMLS CUI [8]
C1257987
subjects taking medications known to affect inflammation and blood lipids (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, hormone replacement, binging alcohol)
Descrição

Pharmaceutical Preparations Affecting Inflammation | Pharmaceutical Preparations Affecting Blood lipids | Steroids | Adrenergic beta-1 Receptor Antagonists | Thiazide Diuretics | Hypolipidemic Agents | Hormone replacement therapy | Alcohol intake above recommended sensible limits

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0021368
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0392760
UMLS CUI [2,3]
C0596192
UMLS CUI [3]
C0038317
UMLS CUI [4]
C0304516
UMLS CUI [5]
C0012802
UMLS CUI [6]
C0086440
UMLS CUI [7]
C0282402
UMLS CUI [8]
C0560219
subjects taking lcn-3pufa supplements within 6 months of study onset.
Descrição

Long chain n-3 PUFA Supplements

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0522095
UMLS CUI [1,2]
C0015689
UMLS CUI [1,3]
C0242295

Similar models

Eligibility Cardiovascular Disease, Inflammation NCT01810003

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Age | Metabolic Syndrome
Item
men and women aged between 18 and 70 years with metabolic syndrome as defined by the international diabetes federation (idf) criteria
boolean
C0001779 (UMLS CUI [1])
C0524620 (UMLS CUI [2])
Stable body weight
Item
stable body weight for at least 3 months prior to randomization.
boolean
C0517386 (UMLS CUI [1])
Premenopausal state | Menstrual cycles regular
Item
pre-menopausal women with regular menstrual cycle (25-35 days)
boolean
C0232969 (UMLS CUI [1])
C2229012 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Plasma C-reactive protein measurement
Item
plasma crp > 10 g/ml at screening
boolean
C0428493 (UMLS CUI [1])
Dyslipidemias Extreme | Hypercholesterolemia, Familial
Item
extreme dyslipidemias such as familial hypercholesterolemia
boolean
C0242339 (UMLS CUI [1,1])
C0205403 (UMLS CUI [1,2])
C0020445 (UMLS CUI [2])
Cardiovascular Disease | Coronary heart disease | Cerebrovascular Disorder | Peripheral Arterial Disease | Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Non-Insulin-Dependent | Insulin | Thiazolidinediones
Item
previous history of cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease) and type 1 or 2 diabetes or patients having received or being treated with insulin or a thiazolidinedione within the past 6 months
boolean
C0007222 (UMLS CUI [1])
C0010068 (UMLS CUI [2])
C0007820 (UMLS CUI [3])
C1704436 (UMLS CUI [4])
C0011854 (UMLS CUI [5])
C0011860 (UMLS CUI [6])
C0021641 (UMLS CUI [7])
C1257987 (UMLS CUI [8])
Pharmaceutical Preparations Affecting Inflammation | Pharmaceutical Preparations Affecting Blood lipids | Steroids | Adrenergic beta-1 Receptor Antagonists | Thiazide Diuretics | Hypolipidemic Agents | Hormone replacement therapy | Alcohol intake above recommended sensible limits
Item
subjects taking medications known to affect inflammation and blood lipids (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, hormone replacement, binging alcohol)
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0021368 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0596192 (UMLS CUI [2,3])
C0038317 (UMLS CUI [3])
C0304516 (UMLS CUI [4])
C0012802 (UMLS CUI [5])
C0086440 (UMLS CUI [6])
C0282402 (UMLS CUI [7])
C0560219 (UMLS CUI [8])
Long chain n-3 PUFA Supplements
Item
subjects taking lcn-3pufa supplements within 6 months of study onset.
boolean
C0522095 (UMLS CUI [1,1])
C0015689 (UMLS CUI [1,2])
C0242295 (UMLS CUI [1,3])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial